Nasdaq GlobeNewswire

Nuvaira Announces Enrollment Completion in First Sham-Controlled Clinical Trial of Targeted Lung Denervation for COPD

Del

MINNEAPOLIS, June 27, 2017 (GLOBE NEWSWIRE) -- Nuvaira (formerly known as Holaira), a developer of medical devices to treat obstructive lung diseases, today announced completion of patient enrollment in the AIRFLOW-2 trial, the first sham-controlled clinical trial of Targeted Lung Denervation* (TLD) using the Nuvaira(TM) Lung Denervation System in patients with moderate to severe chronic obstructive pulmonary disease (COPD). The AIRFLOW-2 (NCT#02058459) trial, designed to assess the safety of TLD in patients suffering from moderate to severe COPD at 16 institutions throughout Western Europe, included 82 patients. 

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4d6d7093-874c-4cac-b8a4-14c7275b566f

COPD is one of the leading causes of morbidity and mortality worldwide. It is characterized by a persistent airflow limitation due to a progressive narrowing of the airways interfering with normal breathing that results in shortness of breath (dyspnea), wheezing, chest tightness, and a productive cough.

"Completing the first randomized, sham-controlled clinical trial of Targeted Lung Denervation is an important milestone to ensure the integrity of scientific data as Nuvaira works to develop a new treatment option for COPD patients," said Jim Pavliska, vice president of Clinical Affairs at Nuvaira. "We are very pleased with the ongoing feedback from the 16 institutions participating in the AIRFLOW-2 trial, as it is providing key insights into optimizing patient selection and procedure workflow for our upcoming pivotal trial, AIRFLOW-3."

The Nuvaira Lung Denervation System is a catheter-based system used to treat the overactive airway nerves during TLD. It is a one-time bronchoscopic procedure that uses the dNerva(TM) Dual Cooled Radiofrequency catheter to provide ablative therapy that opens obstructed airways to improve breathing, and has the potential to provide lasting, whole-lung improvement in patients with moderate to severe COPD.

"We are encouraged by our experience in the AIRFLOW-2 trial using the Nuvaira System," said Professor Felix Herth, M.D., Ph.D., FCCP, chairman, Division of Pulmonology and Respiratory Care Medicine, Thoraxklink, University of Heidelberg. "Because COPD is a progressive disease that affects millions of people and places a significant financial burden on the system, it is imperative that we find better methods of treatment. This new COPD technology may offer a true breakthrough for patients by providing long-term clinical improvement from a one-time procedure," continued Professor Herth.

"TLD is the first medical procedure that targets the whole lung by bronchoscopically disrupting overactive parasympathetic nerves to promote airway dilatation to make it easier to breathe," said Dirk-Jan Slebos, M.D., Ph.D., study principal investigator, University Medical Center, Groningen, The Netherlands. "Our previous research indicates that using Nuvaira's Lung Denervation System is feasible and safe, and there is evidence for a working therapy. In the current study we compared two groups of COPD patients in a sham-controlled manner to show safety and feasibility while separating treatment effect from any placebo effect. Details of the study will be discussed during the September ERS meeting in Milan, Italy."

About COPD
COPD is the umbrella term used to describe a group of diseases such as small airway disease (chronic bronchitis) and emphysema, characterized by chronic and incompletely reversible airway obstruction that interferes with normal breathing. It is estimated that COPD affects 4 to 10 percent of all adults in European countries and more than 300 million people globally1,2.

Pharmacological treatment is the approach for most patients today. Inhaled drugs are used once or twice daily to relax and temporarily open airways. Other forms of treatment include pulmonary rehabilitation, oxygen administration and surgical intervention. These treatments provide temporary relief. The annual financial burden of lung disease in Europe is €141 billion and COPD accounts for almost half3. In the United States, COPD costs are estimated to be more than $50 billion annually4.

About Nuvaira
Nuvaira (formerly known as Holaira) is a privately held company headquartered in Minneapolis, Minn. The company is developing the Nuvaira(TM) Lung Denervation System to address chronic obstructive pulmonary disease (COPD) by treating the overactive airway nerves during Targeted Lung Denervation* (TLD). Nuvaira received CE Mark approval for its Nuvaira Lung Denervation System for use during TLD in January 2016. More information may be found at www.Nuvaira.com.

Institutions Participating in the AIRFLOW-2 Clinical Trial:

Institution Principal Investigator at Site Country
1.  AKH Linz  Bernd Lamprecht, MD  Austria
2.  Otto Wagner Spital  Arschang Valipour, MD**  Austria
3.  CHRU de Lille-Hôpital Calmette  Thierry Perez, MD  France
4.  CHU de Grenoble - Hôpital Michallon  Christoph Pison, MD  France
5.  CHU de Paris - Hôpital Bichat Claude Bernard  Armelle Marceau, MD  France
6.  CHU de Reims - Hôpital Maison Blanche  Gaetan Deslee, MD  France
7.  CHU de Strasbourg - Nouvel Hôpital Civil  Romain Kessler, MD  France
8.  Asklepios-Fachkliniken Munchen Gauting  Wolfgang Gesierich, MD  Germany
9.  Charite-Universitatsmedizin Berlin  Ralf-Harto Huebner, MD  Germany
10. Klinikverbund Kempten Oberallgäu  Christian Schumann, MD  Germany
11. Ruhrlandklinik Essen  Kaid Darwiche, MD  Germany
12. Thoraxklinik Heidelberg  Felix Herth, MD  Germany
13. Universitätsklinikum Bonn  Dirk Skowasch, MD  Germany
14. Academic Medical Center  Peter Bonta, MD  The Netherlands
15. University Medical Center Groningen  Dirk-Jan Slebos, MD**  The Netherlands
16. Royal Brompton & Harefield NHS Foundation Trust  Pallav Shah, MD  United Kingdom

*  Targeted Lung Denervation (TLD) is currently under clinical investigation for chronic obstructive pulmonary disease and is not yet commercially available.

** AIRFLOW-2 Trial Principal Investigators

Nuvaira is a trademark of Nuvaira, Inc.

_____________________________
1 Global Chronic Obstructive Pulmonary Disease Epidemiology and Patient Flow - 2017. Fore Pharma. 
http://www.efanet.org/get-advice/copd 
http://www.efanet.org/get-advice/copd 
4 Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report

Media Contact:
Shane Gleason
Nuvaira
+1 (703-772-3035)
sgleason@Nuvaira.com 




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Nuvaira, Inc via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

SEMAFO Inc. : Q4 and Annual 2017 Production and Costs in Line23.1.2018 00:59Pressemelding

Boungou 80% Complete - Continues on Time, on Budget MONTREAL, Jan. 22, 2018 (GLOBE NEWSWIRE) -- SEMAFO Inc. (TSX:SMF) (OMX:SMF) reports 2017 production of 206,400 ounces at an all-in sustaining cost of $943 per ounce. As a result, the Corporation has beat its revised production and met its cost guidance for the year. Mana In the fourth quarter, Mana produced 49,500 ounces of gold at a total cash cost1 of $667 per ounce and all-in sustaining cost2 of $987 per ounce Annual production of 206,400 ounces, slightly ahead of 2017 guidance of 190,000 to 205,000 ounces Total cash cost1 for 2017 of $655 per ounce All-in sustaining cost2 for 2017 of $943 per ounce, in line with guidance of $920 to $960 per ounce Gold sales of 205,300 ounces generated 2017 revenues of $259 million ($1,261 per ounce) Mining Operations Mana, Burkina Faso Three-month period Year ended December 31, ended December 31, 2017 2016 Variation 2017 2016 Variation Tonnes processed 653,500 714,200 (8%) 2,739,900 2,753,300 - He

Atico Reports 2017 Fourth Quarter and Full Year Production Results22.1.2018 22:30Pressemelding

VANCOUVER, British Columbia, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the "Company" or "Atico") (TSXV:ATY) (OTC:ATCMF) is pleased to announce operating results for the three and twelve month periods ended December 31, 2017 from its El Roble mine. Production totaled 5.33 million pounds of copper with 2,972 ounces of gold for the fourth quarter ("Q4 2017") and 20.63 million pounds of copper with 10,923 ounces of gold in concentrates for the full year 2017. "Atico has successfully concluded its fourth full year of operating the El Roble mine, exceeding 2017 guidance while achieving the highest annual production results to date," said Fernando E. Ganoza, CEO. "In the upcoming year, we will focus on increasing mineral resources through aggressive exploration at the El Roble mine and the surrounding prospective 6,600 hectare land package, to continue growing production and expanding the operation." Fourth Quarter and Full Year Operational Highlights Fourth Quarter Producti

Banque Fédérative du Credit Mutuel: Post Stabilisation Notice22.1.2018 18:54Pressemelding

PARIS, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Banque Fédérative du Credit Mutuel Post Stabilisation Notice HSBC (contact: Syndicate desk, telephone: +44 207 992 8066) hereby gives notice that no stabilisation (within the meaning of the rules of the Financial Conduct Authority) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities. Issuer: Banque Fédérative du Credit Mutuel Guarantor (if any): na Aggregate nominal amount: GBP 450,000,000 Description: 1.375% due Dec 2021 Offer price: 99.872 Stabilising Managers: HSBC & Goldman Sachs This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction This information is provided by RNS The company news service from the London Stock Exchange Contacts: RNS Customer Services 0044-207797-4400 rns@londonstockexchange.com http://www.rns.com This announ

Claroty Wins Inaugural S4 ICS Detection Challenge22.1.2018 18:42Pressemelding

Product Takes Top Spot in both Asset Discovery and Threat Detection Phases NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Claroty, an innovator in operational technology (OT) network protection, today announced that it was crowned winner of the inaugural S4 ICS Detection Challenge, which took place at the S4x18 Conference in Miami. Claroty's Continuous Threat Detection product claimed top honors in both the Phase I - Identification and Phase II - Detection segments of the challenge. During Phase I, contestants consumed network traffic captured from 15 different sites at an unidentified West Coast (U.S.) oil and gas company. The contestants were required to use their products to identify industrial control system (ICS) assets on the network and provide a view of how the assets were communicating. Contestants were rewarded for discovering assets, identifying specific details about them and were given bonus points for unique insights. Scoring was designed to test the products themselves, rat

CEO optimism booms despite increasing anxiety over threats to growth22.1.2018 18:30Pressemelding

· Optimism in global economic growth reaches record level and rises in all countries · US reinforces its lead on China as a target market for growth in 2018 · Over half of CEOs expect their headcount to increase · Terrorism, geopolitical uncertainty, cyber and climate change rise as threats to growth DAVOS, Switzerland, Jan. 22, 2018 (GLOBE NEWSWIRE) -- A record-breaking share of CEOs are optimistic about the economic environment worldwide, at least in the short term. That's one of the key findings of PwC's 21st survey of almost 1,300 CEOs around the world, launched today at the World Economic Forum Annual Meeting in Davos. Fifty seven percent of business leaders say they believe global economic growth will improve in the next 12 months. It's almost twice the level of last year (29%) and the largest ever increase since PwC began asking about global growth in 2012. Optimism in global growth has more than doubled in the US (59%) after a period of uncertainty surrounding the election (201

ShoCard Meets EU's GDPR 'Privacy by Design' Standards through its Identity Management Solutions22.1.2018 16:12Pressemelding

Blockchain-based identity management platform addresses provisions of EU data legislation CUPERTINO, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- ShoCard, a leading blockchain-based identity management system (IMS), today announces its technology meets the European Union's (EU) new regulatory framework for data, known as the General Data Protection Regulation (GDPR), "Privacy by Design" standards. The IMS removes the necessity for authentication data to be stored on organization databases. Instead, it is stored completely on the user's mobile device, secured with their private key and shared via the blockchain. Affected EU-based companies, as well as U.S.-based and other foreign-based companies, processing or holding the personal data of persons residing in the EU, no matter where they are located or where its data is processed within the region, are expected to have GDPR compliant solutions in place ahead of the legislation's enforcement date of May 25, 2018. With user privacy at the cor

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom